<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Acute myeloid leukemia: Classification
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Acute myeloid leukemia: Classification
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Acute myeloid leukemia: Classification
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles A Schiffer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sandeep Gurbuxani, MBBS, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H26564673">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute myeloid leukemia (AML) refers to a heterogenous category of clinically aggressive hematologic neoplasms characterized by accumulation of myeloid blasts in bone marrow, blood, and/or other tissues and distinguished by arrested myeloid maturation. In AML, malignant transformation of myeloid-committed progenitor cells impairs maturation of cells that were otherwise destined to give rise to granulocytic, monocytic, erythroid, and/or megakaryocytic elements.
        </p>
        <p>
         Clinically, AML manifests with symptoms and signs associated with cytopenias (eg, anemia, infections, and/or bleeding or bruising), which may be accompanied by constitutional symptoms, metabolic abnormalities, and various complications. AML has previously been called acute myelogenous leukemia and acute nonlymphocytic leukemia.
        </p>
        <p>
         Cytogenetic and molecular events associated with AML are key elements in the classification of AML subtypes and have important implications for clinical management.
        </p>
        <p>
         This topic describes the classification of AML.
        </p>
        <p>
         Clinical manifestations, diagnosis, pathogenesis, management, and prognosis of AML are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4493.html" rel="external">
          "Acute myeloid leukemia: Pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94786.html" rel="external">
          "Acute myeloid leukemia in adults: Overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2499765659">
         <span class="h1">
          CLINICAL PRESENTATION AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         AML typically manifests with symptoms and signs associated with cytopenias, such as anemia, infections, and/or bleeding. These findings may be accompanied by constitutional symptoms, thrombotic or metabolic complications, massive accumulation of blasts in blood (eg, hyperleukocytosis), or other manifestations.
        </p>
        <p>
         Diagnosis of AML requires evaluation of leukemic blasts from bone marrow, blood, or other disease sites by morphology, immunophenotype, chromosome analysis (karyotype, fluorescence in situ hybridization [FISH]), and molecular testing.
        </p>
        <p>
         Details of the clinical presentation, initial evaluation, and diagnosis of AML are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3934458320">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Development of AML is driven by acquired somatic mutations, along with epigenetic changes in the leukemic cells and alterations in the bone marrow microenvironment. There is increasing recognition of the contributions of inherited (germline) disorders to some cases of AML and related disorders.
        </p>
        <p>
         AML develops from serial acquisition of mutations in hematopoietic stem and progenitor cells that have the capacity to self-renew and propagate the malignant clone [
         <a href="#rid1">
          1,2
         </a>
         ]. In many cases, clonal hematopoiesis, a common premalignant state that increases in prevalence with age, sets the stage for AML [
         <a href="#rid3">
          3
         </a>
         ]. Mutations in
         <em>
          DNMT3A
         </em>
         ,
         <em>
          TET2
         </em>
         , and
         <em>
          ASXL1
         </em>
         are common in clonal hematopoiesis and appear to be relatively early events in leukemogenesis. Mutations in other genes (eg,
         <em>
          FLT3
         </em>
         ,
         <em>
          NRAS
         </em>
         ,
         <em>
          RUNX1
         </em>
         ) generally arise later.
        </p>
        <p>
         Somatic mutations in AML are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4493.html" rel="external">
          "Acute myeloid leukemia: Pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3197172849">
         <span class="h1">
          CLASSIFICATION SYSTEMS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classification schemes for hematologic malignancies continue to evolve with greater insight into pathologic features, pathophysiology, management, and outcomes. Two classification systems for AML were published in 2022 that rely heavily on cytogenetic and molecular features of the leukemic blasts:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemia
         </strong>
         [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          World Health Organization 5th edition (WHO5) myeloid and histiocytic/dendritic neoplasms
         </strong>
         [
         <a href="#rid5">
          5
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Use of
         <strong>
          either
         </strong>
         ICC or WHO5 is acceptable. These models supersede earlier systems, including the prior edition of the WHO classification (revised 4th edition; WHO4R) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Both ICC and WHO5 integrate morphology (cytology, histology, tissue architecture), clinical attributes (eg, acute versus chronic, cytopenias/cytoses), lineage (based on immunophenotype), and cytogenetic and molecular features to categorize AML, myelodysplastic syndromes/neoplasms (MDS), and myeloproliferative neoplasms (MPN).
        </p>
        <p>
         Prior versions of the WHO classification scheme and earlier models (eg, the French-American-British [FAB system] [
         <a href="#rid7">
          7
         </a>
         ], which was prevalent for decades and remains familiar to many clinicians) laid the groundwork for the current models. Earlier systems relied more heavily on clinical features and morphology of leukemic cells, with limited cytogenetic and molecular features.
        </p>
        <p>
         Further discussion of the ICC and WHO5 classification systems is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4716.html" rel="external">
          "Classification of hematopoietic neoplasms"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2276745463">
         <span class="h2">
          International Consensus Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with WHO4R, the ICC moved to a more genetically defined classification system, while retaining many previously defined AML subtypes associated with recurrent/defining genetic abnormalities.
        </p>
        <p>
         Key features and changes associated with ICC include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blast threshold
         </strong>
         – Most cases of AML with defining genetic abnormalities can now be diagnosed with ≥10 percent blasts in blood or bone marrow rather than the previous requirement for ≥20 percent blasts. AML with
         <em>
          BCR::ABL1
         </em>
         fusion is an exception (ie, requiring ≥20 percent blasts), while AML with mutated
         <em>
          TP53
         </em>
         , myelodysplasia-related gene mutations, and myelodysplasia-related cytogenetic abnormalities can define subtypes of AML with 10 to 19 percent blasts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myelodysplastic syndromes/neoplasms/AML
         </strong>
         – This is a new category, in which cases with 10 to 19 percent blasts, but no defining genetic abnormalities, are labeled "MDS/AML." By contrast, WHO5 labels such cases as "MDS with increased blasts-2" (MDS-IB2).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic qualifiers
         </strong>
         – Prior therapy, antecedent myeloid neoplasms (ie, MDS or MDS/MPN), and predisposing germline genetic disorders are added as descriptive qualifiers to the diagnosis of AML, rather than being designated as unique subtypes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           TP53
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – AML with mutated
         <em>
          TP53
         </em>
         is recognized as a distinct entity within a new group of myeloid neoplasms with mutated
         <em>
          TP53
         </em>
         , which also includes MDS and MDS/AML with mutated
         <em>
          TP53
         </em>
         . Acute erythroid leukemia (AEL), which nearly always has mutated
         <em>
          TP53
         </em>
         , was eliminated and subsumed into AML with
         <em>
          TP53
         </em>
         mutation. (See
         <a class="local">
          'Mutated TP53'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           CEBPA
          </em>
         </strong>
         <strong>
          mutations
         </strong>
         – AML with in-frame basic leucine zipper (bZIP) mutations of
         <em>
          CEBPA
         </em>
         no longer requires biallelic mutations. (See
         <a class="local">
          'Mutated CEBPA'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subtypes redefined
         </strong>
         – AML with somatic
         <em>
          RUNX1
         </em>
         mutation was included in the broad category of AML with myelodysplasia-related gene mutations. Both ICC and WHO5 recognize that morphologic dysplasia alone is no longer sufficient for a diagnosis of AML with myelodysplasia-related changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special categories
         </strong>
         – Presence of an extramedullary mass of myeloid blasts (myeloid sarcoma) is sufficient to diagnose AML. (See
         <a class="local">
          'Myeloid sarcoma'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Myeloid neoplasms associated with Down syndrome and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are considered distinct diagnoses. (See
         <a class="local">
          'Myeloid proliferations related to Down syndrome'
         </a>
         below and
         <a class="local">
          'Other AML subtypes in International Consensus Classification'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1544090386">
         <span class="h2">
          World Health Organization 5th edition
         </span>
         <span class="headingEndMark">
          —
         </span>
         WHO5 emphasizes genetically defined criteria for classification of AML, while cases without such features are classified according to the differentiation of the leukemic blasts. AML is organized according to the following major groups by WHO5:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AML with defining genetic abnormalities
         </strong>
         – WHO5 eliminated the 20 percent blast threshold for the diagnosis of AML with defining genetic abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the 20 percent blast threshold was retained for AML with
         <em>
          CEBPA
         </em>
         mutations (to distinguish this from MDS with mutated
         <em>
          CEBPA
         </em>
         ) and for AML with
         <em>
          BCR::ABL1
         </em>
         (to avoid overlap with chronic myeloid leukemia [CML] presenting in advanced phase of disease).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         WHO5 also created a new subtype, called AML with other defined genetic alterations, which serves as a landing spot for new and/or uncommon AML subtypes, which require further confirmation in future studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AML defined by differentiation
         </strong>
         – For AML that lacks a defining genetic abnormality, AML subtypes are labeled according to the state of differentiation. All such cases require ≥20 percent blasts, except for AEL. (See
         <a class="local">
          'Other AML subtypes in World Health Organization 5th edition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         WHO5 labels cases with no defining genetic abnormality but with 10 to 19 percent blasts as MDS-IB2; this differs from ICC, which labels such cases as MDS/AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subtypes
         </strong>
         <strong>
          eliminated
         </strong>
         – WHO5 eliminated AML, not otherwise specified (AML, NOS), which was replaced by subtypes according to the stage of differentiation. (See
         <a class="local">
          'Other AML subtypes in World Health Organization 5th edition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H493999245">
         <span class="h2">
          Comparison of International Consensus Classification and World Health Organization 5th edition
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICC and WHO5 have similar, but distinct, systems for organizing categories of AML, and they differ regarding certain diagnostic criteria and labels for subtypes.
        </p>
        <p>
         Neither system requires ≥20 percent blasts for many AML with defining genetic abnormalities, and both eliminated AML with myelodysplasia-related changes and AML with somatic
         <em>
          RUNX1
         </em>
         mutation.
        </p>
        <p>
         Key differences between ICC and WHO5 include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AML with defining genetic characteristics
         </strong>
         – Both systems classify most cases of AML according to a defining genetic abnormality. (See
         <a class="local">
          'AML with defining genetic abnormalities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus classification
         </strong>
         – More specific labels are used for certain subtypes with defining genetic abnormalities. As an example, acute promyelocytic leukemia (APL) with t(15;17)/
         <em>
          PML::RARA
         </em>
         is distinct from APL with other
         <em>
          RARA
         </em>
         rearrangements; by contrast, all cases of APL are grouped as a single subtype by WHO5.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – A new category, AML with other defined genetic abnormalities, serves as a placeholder for AML with uncommon genetic findings that require further characterization and confirmation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AML without defining genetic abnormalities
         </strong>
         – With more subtypes based on distinctive genetic characteristics, the fraction of cases without a defining genetic abnormality decreased substantially in both systems.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – AML, NOS was retained as a subtype for cases with ≥20 percent blasts but no defining genetic abnormality. Cases with 10 to 19 percent blasts are now described as MDS/AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – AML, NOS was eliminated as a category and replaced with eight subtypes that are defined by the state of differentiation. (See
         <a class="local">
          'Other AML subtypes in World Health Organization 5th edition'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Pure erythroid leukemia, which almost always has mutated
         <em>
          TP53
         </em>
         , was eliminated in ICC and is, instead, subsumed into AML with
         <em>
          TP53
         </em>
         mutation. WHO5 retained this as a differentiation-based category, now labeled AEL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Therapy-related AML
         </strong>
         – AML that arises after cytotoxic treatment generally carries an adverse prognosis. (See
         <a class="local">
          'Therapy-related AML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For such cases:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – "Therapy-related" is added as a qualifier after a diagnosis of AML, MDS, or MDS/AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Treatment-related myeloid neoplasms constitute a new subtype, "myeloid neoplasms postcytotoxic therapy" that is included among "secondary myeloid neoplasms." Assignment to subtypes in this category is based on medical history rather than morphologic and/or genetic features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloid neoplasms with mutated
         </strong>
         <strong>
          <em>
           TP53
          </em>
         </strong>
         – Mutations of TP53 carry an adverse prognosis. (See
         <a class="local">
          'Mutated TP53'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For such cases:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – A new category, "myeloid neoplasms with
         <em>
          TP53
         </em>
         abnormalities" includes subtypes that are classified according to the percentage of blasts (ie, &lt;10 percent [MDS], 10 to 19 percent [MDS/AML], ≥20 percent [AML]).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Myeloid neoplasms with
         <em>
          TP53
         </em>
         abnormalities are labeled as AML or MDS according to the percentage of blasts. AML with
         <em>
          TP53
         </em>
         mutations is described in multiple categories, including AEL and secondary myeloid neoplasms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Disorders associated with
         </strong>
         <strong>
          germline pathogenic gene variants
         </strong>
         . (See
         <a class="local">
          'Predisposing genetic conditions'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – A new category, "pediatric and/or germline mutation-associated disorders," includes disorders such as juvenile myelomonocytic leukemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – "Associated with germline (gene) variant" is added as a modifier to the category label (eg, AML, MPN, MDS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloid proliferations related to Down syndrome
         </strong>
         . (See
         <a class="local">
          'Myeloid proliferations related to Down syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – Myeloid proliferations associated with Down syndrome comprise a new category in ICC that includes transient abnormal myelopoiesis (TAM) associated with Down syndrome and myeloid leukemia associated with Down syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – These disorders are included in "myeloid neoplasms associated with germline predisposition."
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H460783932">
         <span class="h2">
          Implications for clinicians
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, differences between the ICC and WHO5 classification systems are modest, but they have implications for clinicians. Importantly, both systems recognize the biologic and clinical overlap between advanced stages of MDS and AML with lower blast counts and certain genetic findings (eg, mutated
         <em>
          TP53
         </em>
         ) that confer a poor prognosis.
        </p>
        <p>
         However, the following distinctions between ICC and WHO5 should be kept in mind:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical trials
         </strong>
         – The different defining blast thresholds that distinguish MDS from AML may affect eligibility criteria in future clinical trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nevertheless, contemporary trials increasingly permit enrollment of patients with advanced MDS in AML trials. The implications of different diagnostic thresholds between ICC and WHO5 were acknowledged in WHO5, which stated, "there was broad agreement that MDS-IB2 may be regarded as AML-equivalent for therapeutic considerations and from a clinical trial design perspective when appropriate" [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical care
         </strong>
         – For nonprotocol-directed clinical care, treatment decisions should continue to be guided by medical comorbidities, age, and cytogenetic and molecular prognostic factors rather than the labels MDS or AML, per se. These treatment decisions are often difficult, but the distinction between &gt;10 percent blasts and &gt;20 percent blasts should only infrequently be the deciding factor in guiding management of such patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This importance of age, fitness, and genetic features for guiding treatment decisions is especially important for less-fit individuals, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4530.html" rel="external">
          "Acute myeloid leukemia: Management of medically unfit adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26565145">
         <span class="h1">
          AML WITH DEFINING GENETIC ABNORMALITIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The large category of AML with defining genetic abnormalities accounts for most cases of AML in both the International Consensus Classification (ICC) and World Health Organization 5th edition (WHO5) systems.
        </p>
        <p>
         Most cases of AML with defining genetic abnormalities can be diagnosed with ≥10 percent blasts in marrow or blood. Notable exceptions are AML with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          BCR::ABL1
         </em>
         fusion (in both ICC and WHO5).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mutated
         <em>
          TP53
         </em>
         (in ICC; labeled AML with ≥20 percent blasts versus MDS/AML for cases with 10 to 19 percent blasts).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myelodysplasia-related gene mutations (in ICC; ie,
         <em>
          ASXL1
         </em>
         ,
         <em>
          BCOR
         </em>
         ,
         <em>
          EZH2
         </em>
         ,
         <em>
          RUNX1
         </em>
         ,
         <em>
          SF3B1
         </em>
         ,
         <em>
          SRSF2
         </em>
         ,
         <em>
          STAG2
         </em>
         ,
         <em>
          U2AF1
         </em>
         , or
         <em>
          ZRSR2
         </em>
         , which are distinguished from MDS/AML with 10 to 19 percent blasts).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myelodysplasia-related cytogenetic abnormalities (in ICC; defined by a complex karyotype [≥3 unrelated clonal chromosomal abnormalities in the absence of other class-defining recurring genetic abnormalities], del[5q]/t[5q]/add[5q], -7/del[7q], +8, del[12p]/t[12p]/add[12p], i[17q], -17/add[17p] or del[17p], del[20q], and/or idic[X][q13] clonal abnormalities), which are distinguished from cases of MDS/AML with myelodysplasia-related cytogenetic abnormalities (10 to 19 percent blasts).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AML, not otherwise specified (AML, NOS; in ICC, which are distinguished from MDS/AML with 10 to 19 percent blasts).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AML with
         <em>
          CEBPA
         </em>
         mutation (in WHO5).
        </p>
        <p>
        </p>
        <p>
         There are also differences in the naming of these subtypes (eg, ICC includes the characteristic chromosomal and molecular rearrangement for many subtypes, whereas WHO5 labels include only the molecular rearrangements).
        </p>
        <p>
         The following are categories of AML with defining genetic abnormalities, noting significant differences between the systems.
        </p>
        <p class="headingAnchor" id="H4054245612">
         <span class="h2">
          Acute promyelocytic leukemia with
          <i>
           PML::RARA
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute promyelocytic leukemia (APL) with
         <em>
          PML::RARA
         </em>
         is a unique clinicopathologic entity that often presents with a coagulopathy and is characterized by the infiltration of the bone marrow by promyelocytes with the
         <em>
          PML::RARA
         </em>
         fusion gene [
         <a href="#rid6">
          6
         </a>
         ]. The rearrangement links the retinoic acid receptor alpha (
         <em>
          RARA
         </em>
         ) gene on chromosome 17 with the promyelocytic leukemia (
         <em>
          PML
         </em>
         ) gene on chromosome 15, and it is uniquely responsive to treatment with
         <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">
          all-trans retinoic acid
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences between International Consensus Classification and World Health Organization 5th edition
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – Distinguishes APL with t(15;17)(q24.1;q21.2)/
         <em>
          PML::RARA
         </em>
         versus cases of APL with other
         <em>
          RARA
         </em>
         rearrangements.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Describes only one subtype (ie, APL with
         <em>
          PML::RARA
         </em>
         fusion).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – Cases are frequently associated with disseminated intravascular coagulation (DIC) and fibrinolysis. APL with
         <em>
          PML::RARA
         </em>
         accounts for up to 13 percent of newly diagnosed AML [
         <a href="#rid8">
          8
         </a>
         ]. Clinical manifestations of APL are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4527.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow appearance
         </strong>
         – Abnormal promyelocytes predominate in the marrow. There are hypergranular or microgranular variants of APL.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloblasts
         </strong>
         – A characteristic folded, reniform (kidney-shaped), or bilobed nucleus may be found in promyelocytes; coarse azurophilic granules and multiple Auer rods are also common  (
         <a class="graphic graphic_picture graphicRef82863" href="/z/d/graphic/82863.html" rel="external">
          picture 1
         </a>
         ). Cytoplasmic granules in promyelocytes may be so prominent that they obscure the nuclear-cytoplasmic border. The less-common microgranular variant of APL contains smaller, less-apparent cytoplasmic granules and bilobed nuclei  (
         <a class="graphic graphic_picture graphicRef82867" href="/z/d/graphic/82867.html" rel="external">
          picture 2
         </a>
         ), which can occasionally be confused with monocytic morphology.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Hypergranular variants are CD33 positive, CD64 positive; have variable levels of CD13 expression; low expression of HLA (human leukocyte antigen)-DR, CD34, and leukocyte integrins (CD11a, CD11b, CD18); and usually present with low white blood cell (WBC) counts. Microgranular variants can have CD34 or CD2 expression on some cells and often present with high WBC counts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – Nearly all cases are associated with t(15;17)(q24.1;q21.2), but the WHO5 nomenclature recognizes that
         <em>
          PML::RARA
         </em>
         may also result from complex cytogenetic rearrangements. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities", section on 't(15;17); PML::RARA'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Cases with morphology resembling APL, but with variant translocations that are not uniformly responsive to retinoic acid [
         <a href="#rid9">
          9
         </a>
         ], are labeled APL with other
         <em>
          RARA
         </em>
         rearrangements in ICC but are classified as APL in WHO5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – There is risk of early death from DIC, but treatment using
         <a class="drug drug_general" data-topicid="9262" href="/z/d/drug information/9262.html" rel="external">
          all-trans retinoic acid
         </a>
         , with or without
         <a class="drug drug_general" data-topicid="8977" href="/z/d/drug information/8977.html" rel="external">
          arsenic trioxide
         </a>
         , is usually associated with favorable outcomes. APL represents a medical emergency, but if managed appropriately, it has a favorable prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of APL is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4498.html" rel="external">
          "Initial treatment of acute promyelocytic leukemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1574929825">
         <span class="h2">
          t(8;21)/
          <i>
           RUNX1::RUNX1T1
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         The finding of t(8;21)(q22;q22),
         <em>
          RUNX1::RUNX1T1
         </em>
         is diagnostic for AML, in the presence of ≥10 percent blasts.
        </p>
        <p>
         AML with t(8;21) identifies a morphologically and clinically distinct subset of AML with the following features [
         <a href="#rid6">
          6,10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – The balanced translocation t(8;21)(q22;q22),
         <em>
          RUNX1::RUNX1T1
         </em>
         (previously
         <em>
          AML1::ETO
         </em>
         ), accounts for 7 percent of adults with newly diagnosed AML  (
         <a class="graphic graphic_figure graphicRef53821" href="/z/d/graphic/53821.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ]. t(8;21) is the most frequent cytogenetic abnormality in children with AML (12 to 15 percent) [
         <a href="#rid11">
          11,12
         </a>
         ]. Myeloid sarcoma can be present at diagnosis. Compared with other subtypes, patients with AML with
         <em>
          RUNX1::RUNX1T1
         </em>
         may have lower leukocyte counts, hemoglobin, and blast counts [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow appearance
         </strong>
         – This subtype has no diagnostic morphologic features, but promyelocytes, myelocytes, and metamyelocytes are present and may sometimes include fine Auer rods. Eosinophils may be increased but show no morphologic abnormalities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloblasts
         </strong>
         – The large myeloblasts tend to have indented nuclei, abundant basophilic cytoplasm with numerous azurophilic granules, and a prominent paranuclear clear zone. Auer rods, which appear as single long rods with tapered ends, are common and may be found in blasts and maturing neutrophils. Abnormal nuclear segmentation (pseudo-Pelger-Huët nuclei), very large cytoplasmic granules (pseudo-Chediak-Higashi granules), and/or abnormal cytoplasmic staining (eg, homogeneous, salmon-colored cytoplasm with blue rims in maturing neutrophils) may be seen, but dysplasia in other lineages is uncommon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Most cases have a subpopulation of blasts that express abundant CD34, HLA-DR, myeloperoxidase (MPO), and CD13 but weak expression of CD33 [
         <a href="#rid15">
          15
         </a>
         ]. This leukemia can coexpress lymphoid markers (eg, CD19, PAX5, cytoplasmic CD79) [
         <a href="#rid16">
          16-18
         </a>
         ], but this should not be construed as evidence for a mixed phenotype. CD56 is expressed in a fraction of cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – Even if t(8;21) is not observed by karyotypic analysis, fluorescence in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RT-PCR) demonstrate the cryptic
         <em>
          RUNX1::RUNX1T1
         </em>
         rearrangement. More than two-thirds of cases show additional cytogenetic abnormalities, including loss of a sex chromosome or del(9q) [
         <a href="#rid19">
          19
         </a>
         ]. Further description of this translocation is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities", section on 't(8;21); RUNX1::RUNX1T1'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – This leukemia is associated with a favorable prognosis [
         <a href="#rid20">
          20
         </a>
         ]. The presence of
         <em>
          KIT
         </em>
         mutations is an adverse prognostic feature in patients with t(8;21). Patients can have
         <em>
          RUNX1-RUNX1T1
         </em>
         transcripts detected by RT-PCR, even when they have been in remission for many years; this finding does not always predict relapse [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Familial platelet disorder with propensity to myeloid malignancies is an autosomal dominant syndrome caused by germline monoallelic mutations in
         <em>
          RUNX1
         </em>
         that typically presents with longstanding mild to moderate thrombocytopenia, a mild bleeding propensity (due to an aspirin-like functional platelet defect), and increased risk of developing MDS, AML, and T cell acute lymphoblastic leukemia (ALL). This familial disorder is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial platelet disorder with propensity to myeloid malignancies (FPD)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2205363217">
         <span class="h2">
          inv(16)(p13.1q22) or t(16;16)(p13.1;q22);
          <i>
           CBFB::B-MYH11
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         AML with these chromosome 16 abnormalities usually exhibit monocytic and granulocytic differentiation with morphologically abnormal eosinophils. These leukemias were previously classified as acute myelomonocytic leukemia with abnormal eosinophils (AMML; FAB M4Eo).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – Abnormalities of chromosome 16 are seen in approximately 5 percent of adults with newly diagnosed AML  (
         <a class="graphic graphic_figure graphicRef53821" href="/z/d/graphic/53821.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ]. It is more common in younger patients and can present as an extramedullary myeloid sarcoma; some studies have reported an increased incidence of central nervous system involvement [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow appearance
         </strong>
         – In addition to the typical morphologic features of AML, bone marrow demonstrates abnormal eosinophils, including all stages of eosinophilic maturation (ie, there is generally no maturation arrest) and immature eosinophilic granules seen in the promyelocyte and myelocyte stages of development [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloblasts
         </strong>
         – Myeloblasts have a significant monocytic component (which may be nonspecific esterase [NSE] reaction negative). There are variable numbers of abnormal immature eosinophils with large, atypical, purple-violet cytoplasmic granules  (
         <a class="graphic graphic_picture graphicRef71045" href="/z/d/graphic/71045.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – The immunophenotype is often complex with multiple blast populations: immature blasts (CD34 positive, CD117 positive) and populations that are more granulocytic (expression of CD13, CD33, CD15, CD65, and/or MPO) or monocytic (expression of CD14, CD4, CD11b, CD11c, CD64, CD36, and/or lysozyme).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – AML with inv(16)(p13.1q22) accounts for the majority of this AML subtype; t(16;16)(p13.1;q22);
         <em>
          CBFB::MYH11
         </em>
         is much less common. Further details regarding these translocations are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities", section on 'inv(16) or t(16;16); CBFB::MYH11'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – This leukemia is associated with more favorable outcomes, but cases with a
         <em>
          KIT
         </em>
         mutation may do more poorly [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4176122883">
         <span class="h2">
          t(9;11)(p21.3;q23.3);
          <i>
           MLLT3::KMT2A
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         This subtype is associated with
         <em>
          KMT2A::MLLT3
         </em>
         fusion and generally has monocytic features.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences between International Consensus Classification and World Health Organization 5th edition
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – Distinguishes between cases with
         <strong>
         </strong>
         t(9;11)(p21.3;q23.3)/
         <em>
          MLLT3::KMT2A
         </em>
         versus other
         <em>
          KMT2A
         </em>
         rearrangements.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Labeled AML with
         <em>
          KMT2A
         </em>
         rearrangement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – t(9;11) is more common in children (9 to 12 percent) than in adults (2 percent) [
         <a href="#rid8">
          8,24
         </a>
         ]. Patients may present with DIC, infiltration of gingiva or skin with leukemic cells, or myeloid sarcoma.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow appearance
         </strong>
         – Monoblasts and promonocytes usually predominate in the marrow; promonocytes are considered blast equivalents. Monoblasts and promonocytes stain with NSE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Most pediatric cases express HLA-DR, CD33, CD65, and CD4, with low level expression of myeloid markers (eg, CD13, CD14) [
         <a href="#rid26">
          26
         </a>
         ]. Adult cases express more markers of monocytic differentiation, with variable expression of CD34 and CD117 [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – t(9;11)(p21.3;q23.3) may be accompanied by secondary cytogenetic abnormalities, such as gain of chromosome 8 [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          KMT2A
         </em>
         (previously known as
         <em>
          ALL-1
         </em>
         or
         <em>
          MLL-1
         </em>
         ) has been involved in &gt;80 different translocations [
         <a href="#rid30">
          30
         </a>
         ]. Further details regarding translocations involving
         <em>
          KMT2A
         </em>
         are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities", section on 't(9;11); KMT2A::MLLT3'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – t(9;11)(p21.3;q23.3) is associated with an intermediate survival.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3830926935">
         <span class="h2">
          AML with t(6;9)(p22.3;q34.1)/
          <i>
           DEK::NUP214
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         This subtype is associated with the
         <em>
          DEK::NUP214
         </em>
         rearrangement and can exhibit monocytic features, basophilia, or multilineage dysplasia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – This subtype is seen in 1 percent of adults and 10 percent of children with newly diagnosed AML [
         <a href="#rid8">
          8,31
         </a>
         ]. Patients may present with pancytopenia and lower leukocyte counts than other AML subtypes [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow appearance
         </strong>
         – Bone marrow presents with variable morphology, basophilia, and single or multilineage dysplasia [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloblasts
         </strong>
         – Myeloblasts are positive for MPO.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – The tumor cells typically express CD13, CD33, CD38, CD45, and HLA-DR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – There is a high incidence of
         <em>
          FLT3
         </em>
         internal tandem duplications (ITD) [
         <a href="#rid33">
          33
         </a>
         ]. Details of this translocation are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">
          "Acute myeloid leukemia: Cytogenetic abnormalities", section on 't(6;9); DEK::NUP214'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – AML with t(6;9)(p23;q34);
         <em>
          DEK-NUP214
         </em>
         has a poor prognosis [
         <a href="#rid8">
          8,31,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2627184831">
         <span class="h2">
          inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);
          <i>
           GATA2
          </i>
          ,
          <i>
           MECOM
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         These karyotypic findings are associated with deregulated expression of
         <em>
          MECOM
         </em>
         (also called
         <em>
          EVI1
         </em>
         ); patients may present with normal or elevated platelet counts.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences between International Consensus Classification and World Health Organization 5th edition
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – Distinguishes between AML with inv(3)(q21.3q26.2) or AML with t(3;3)(q21.3;q26.2)/
         <em>
          GATA2
         </em>
         ;
         <em>
          MECOM
         </em>
         (
         <em>
          EVI1
         </em>
         ) versus AML with other
         <em>
          MECOM
         </em>
         rearrangements.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th
         </strong>
         <strong>
          edition
         </strong>
         – This is a single subtype in WHO5.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – This subset accounts for 1 to 2 percent of AML [
         <a href="#rid28">
          28,35
         </a>
         ]. Giant, hypogranular platelets are common, and megakaryocytic nuclei and hypogranular neutrophils with pseudo-Pelger-Huët anomaly may be seen in blood.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow appearance
         </strong>
         – Megakaryocytes may be dysplastic and increased in number, with nonlobated or bilobed nuclei [
         <a href="#rid36">
          36-38
         </a>
         ]. There may be multilineage dysplasia in nonblast cells. Cellularity and fibrosis are variable, and eosinophils, basophils, or mast cells may be increased in the marrow.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This abnormality may be seen in de novo AML and in therapy-related MDS/AML. (See
         <a class="local">
          'Therapy-related AML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloblasts
         </strong>
         – Blasts may be variable in appearance, with minimal differentiation and myelomonocytic or megakaryoblastic features.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Blasts are positive for CD34, CD33, CD13, CD117, and HLA-DR; most express CD38. A subset of cases expresses megakaryocytic markers (eg, CD41, CD61).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetics
         </strong>
         – A variety of abnormalities of the long arm of chromosome 3 may be found  (
         <a class="graphic graphic_figure graphicRef53821" href="/z/d/graphic/53821.html" rel="external">
          figure 1
         </a>
         ). The abnormalities reposition an enhancer of
         <em>
          GATA2
         </em>
         to activate
         <em>
          MECOM
         </em>
         expression and result in functional haploinsufficiency of
         <em>
          GATA2
         </em>
         [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A familial form of AML caused by monoallelic mutations in
         <em>
          GATA2
         </em>
         is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial MDS/AML with mutated GATA2'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – This is an aggressive subset of AML with generally poor prognosis [
         <a href="#rid41">
          41-44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1205996621">
         <span class="h2">
          <i>
           BCR::ABL1
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         This category requires ≥20 percent blasts in both ICC and WHO5.
        </p>
        <p>
         The Philadelphia chromosome, t(9;22)(q34;q11.2), or
         <em>
          BCR::ABL1
         </em>
         gene rearrangement is found in a small percentage of patients with apparently de novo AML (2 percent), a higher percentage of patients with mixed-phenotype acute leukemia (38 percent), and is associated with adverse outcomes [
         <a href="#rid45">
          45,46
         </a>
         ]. On genomic analysis, these cases display some abnormalities also seen in ALL, including deletions in
         <em>
          IKZF1
         </em>
         and
         <em>
          CDNK1A/B
         </em>
         [
         <a href="#rid47">
          47
         </a>
         ]. Unlike chronic myeloid leukemia (CML; at any phase), cases of AML and ALL with
         <em>
          BCR::ABL1
         </em>
         display concomitant loss of
         <em>
          IGH
         </em>
         /
         <em>
          VDJ
         </em>
         and
         <em>
          TARP
         </em>
         regions; these findings support the identification of AML with
         <em>
          BCR::ABL1
         </em>
         as an entity that is distinct from CML myeloid blast crisis.
        </p>
        <p>
         CML blast crisis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4512.html" rel="external">
          "Treatment of chronic myeloid leukemia in blast crisis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1913042973">
         <span class="h2">
          Mutated
          <i>
           NPM1
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nucleophosmin gene (
         <em>
          NPM1
         </em>
         ) abnormalities define a subtype of AML but may also be seen in cases of MDS or chronic myelomonocytic leukemia.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         –
         <em>
          NPM1
         </em>
         mutation is found in 2 to 8 percent of childhood AML and 27 to 35 percent of adult AML [
         <a href="#rid48">
          48
         </a>
         ]. Patients often have higher WBC counts than other subtypes of AML [
         <a href="#rid49">
          49
         </a>
         ]. There may be extramedullary involvement (eg, gingiva, skin, lymph nodes).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow
         </strong>
         – The bone marrow is hypercellular, and blasts frequently exhibit myelomonocytic or monocytic features. Multilineage dysplasia is present in one-quarter of cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Immunostaining with anti-NPM1 antibodies reveals involvement of ≥2 lineages in most cases [
         <a href="#rid50">
          50
         </a>
         ]. Blasts express CD33 and may express CD117, CD123, and CD110 [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The presence of the
         <em>
          NPM1
         </em>
         mutation generally confers a favorable prognosis; however, when mutated
         <em>
          NPM1
         </em>
         occurs in conjunction with mutations in
         <em>
          FLT3
         </em>
         , the prognosis is worse than in patients who only have the
         <em>
          NPM1
         </em>
         mutation [
         <a href="#rid6">
          6,10,48
         </a>
         ]. The prognostic impact of
         <em>
          NPM1
         </em>
         mutations is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'NPM1'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4117531497">
         <span class="h2">
          Mutated
          <i>
           CEBPA
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         This subtype is defined by a basic leucine zipper (bZip) mutation of
         <em>
          CEBPA
         </em>
         . Most cases of AML with mutated
         <em>
          CEBPA
         </em>
         exhibit little maturation, but some manifest myelomonocytic or monoblastic features.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences between International Consensus Classification and World Health Organization 5th edition
         </strong>
         – Biallelic bZip
         <em>
          CEBPA
         </em>
         mutations are no longer required in either ICC or WHO5 (ie, a single mutation in the bZip region is sufficient for diagnosis).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – Diagnosis requires ≥10 percent blasts.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – AML with
         <em>
          CEBPA
         </em>
         mutation can be diagnosed irrespective of the blast count, with appropriate clinicopathologic correlation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – Biallelic mutations of
         <em>
          CEBPA
         </em>
         are present in 4 to 9 percent of children and young adults [
         <a href="#rid52">
          52,53
         </a>
         ]; it is less common in older patients. Patients may present with a higher level of hemoglobin and lower platelet counts than other AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow
         </strong>
         – There are no distinctive morphologic features. Most cases exhibit little or no maturation, and multilineage dysplasia is present in one-quarter of cases [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunophenotype
         </strong>
         – Cases with biallelic
         <em>
          CEBPA
         </em>
         mutation have little or no expression of some monocytic markers, such as CD14. There may be significant expression of CD7, CD15, CD64, and HLA-DR [
         <a href="#rid52">
          52,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – This subtype of AML is associated with a favorable prognosis. The prognostic impact of
         <em>
          CEBPA
         </em>
         mutations is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4516.html" rel="external">
          "Acute myeloid leukemia: Risk factors and prognosis", section on 'CEBPA'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Familial AML with mutated
         <em>
          CEBPA
         </em>
         is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes", section on 'Familial AML with mutated CEBPA'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3969918939">
         <span class="h2">
          Mutated
          <i>
           TP53
          </i>
         </span>
         <span class="headingEndMark">
          —
         </span>
         ICC and WHO5 differ in how they label AML with
         <em>
          TP53
         </em>
         mutations
         <em>
          .
         </em>
         <em>
          TP53
         </em>
         mutations negatively influence prognosis of myeloid neoplasms independent of the blast count, and they may arise in the setting of previous cytotoxic treatments, germline disorders, MDS, or without any predisposing condition.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences between International Consensus Classification and World Health Organization 5th edition
         </strong>
         – ICC and WHO5 differ in how they classify AML with mutated
         <em>
          TP53
         </em>
         . ICC created a new category, "myeloid malignancies with
         <em>
          TP53
         </em>
         abnormalities." By contrast, WHO5 does not have a specific category for cases with mutated
         <em>
          TP53
         </em>
         but acknowledges that many patients are included among those with 17p abnormalities or therapy-related secondary AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – ICC created a new category, "myeloid malignancies with
         <em>
          TP53
         </em>
         mutations," in recognition of the shared biology and treatment responses of these conditions. It further subclassifies them according to the percentage of blasts, as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         MDS with mutated
         <em>
          TP53
         </em>
         – &lt;10 percent blasts with multihit
         <em>
          TP53
         </em>
         mutation (ie, two distinct
         <em>
          TP53
         </em>
         mutations, each with variant allele fraction [VAF] &gt;10 percent
         <strong>
          or
         </strong>
         a single
         <em>
          TP53
         </em>
         mutation with either 17p deletion, VAF &gt;50 percent, or copy-neutral loss of heterozygosity at the 17p
         <em>
          TP53
         </em>
         locus)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         MDS/AML with mutated
         <em>
          TP53
         </em>
         – 10 to 19 percent blasts
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         AML with mutated
         <em>
          TP53
         </em>
         – &gt;20 percent blasts
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         While mutations of both
         <em>
          TP53
         </em>
         alleles are required to diagnose MDS with mutated
         <em>
          TP53
         </em>
         , any pathogenic
         <em>
          TP53
         </em>
         mutation with VAF &gt;10 percent is sufficient to diagnose AML and MDS/AML with mutated
         <em>
          TP53
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Myeloid disorders with
         <em>
          TP53
         </em>
         mutations are included in various categories of AML or MDS. There is no specific subtype of AML with mutated
         <em>
          TP53
         </em>
         in WHO5, but the monograph acknowledges that MDS with multiple
         <em>
          TP53
         </em>
         abnormalities may be regarded as being equivalent to AML for treatment purposes.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2542390601">
         <span class="h2">
          Myelodysplasia-related gene mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following mutations are considered myelodysplasia-related in both ICC and WHO5:
         <em>
          ASXL1
         </em>
         ,
         <em>
          BCOR
         </em>
         ,
         <em>
          EZH2
         </em>
         ,
         <em>
          SF3B1
         </em>
         ,
         <em>
          SRSF2
         </em>
         ,
         <em>
          STAG2
         </em>
         ,
         <em>
          U2AF1
         </em>
         ,
         <em>
         </em>
         or
         <em>
          ZRSR2
         </em>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – In addition to those listed above,
         <em>
          RUNX1
         </em>
         mutations are considered myelodysplasia related. ICC distinguishes cases according to the percentage of blasts:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         AML with myelodysplasia-related mutations – ≥20 percent blasts
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         MDS/AML with myelodysplasia-related mutations – 10 to 19 percent blasts
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization
         </strong>
         – In the presence of ≥20 percent blasts, the mutations listed above are sufficient to diagnose AML with myelodysplasia-related gene mutation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In WHO, morphology alone is no longer sufficient to diagnose myelodysplasia-related AML; this subtype and AML with myelodysplasia-related cytogenetic abnormalities replaced the former category, "AML, myelodysplasia-related." (See
         <a class="local">
          'Myelodysplasia-related cytogenetic abnormalities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2242593681">
         <span class="h2">
          Myelodysplasia-related cytogenetic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following karyotypic abnormalities are considered myelodysplasia-related in both ICC and WHO5: complex karyotype (≥3 unrelated clonal chromosomal abnormalities), del(5q)/t(5q)/add(5q), -7/del(7q), +8, del(12p)/t(12p)/add(12p), i(17q), -17/add(17p) or del(17p), del(20q), and/or idic(X)(q13) clonal abnormalities.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differences
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus classification
         </strong>
         – ICC distinguishes such cases according to the percentage of blasts:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         AML with myelodysplasia-related cytogenetic abnormalities – ≥20 percent blasts
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         MDS/AML with myelodysplasia-related cytogenetic abnormalities – 10 to 19 percent blasts
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization
         </strong>
         – This subtype is defined as a malignancy with ≥20 percent blasts expressing a myeloid immunophenotype and harboring the designated cytogenetic abnormalities associated with MDS, which arise de novo or following a known history of MDS or MDS/myeloproliferative neoplasms (MPN).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H422852411">
         <span class="h2">
          Other genetic abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Less common mutations are categorized differently by ICC and WHO5.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – AML with other rare recurring translocations require ≥10 percent blasts and are classified as "AML with other rare recurring translocations."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – The following are considered separate subtypes in WHO5:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         AML with
         <em>
          RBM15::MRTFA
         </em>
         fusion
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         AML with
         <em>
          NUP98
         </em>
         rearrangement
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         AML with other defined genetic alterations
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1997152329">
         <span class="h1">
          OTHER SUBTYPES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cases of AML that do not meet the criteria for defining genetic abnormalities are classified differently by the International Consensus Classification (ICC) and World Health Organization 5th edition (WHO5).
        </p>
        <p>
         AML with defining genetic abnormalities is described above. (See
         <a class="local">
          'AML with defining genetic abnormalities'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H725725030">
         <span class="h2">
          Other AML subtypes in International Consensus Classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classification of cases of AML that do not have defining genetic abnormalities and certain other categories of myeloid malignancies are described as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AML, not otherwise specified
         </strong>
         – ICC retained the category AML, not otherwise specified (AML, NOS) to accommodate cases that do not meet the criteria for defining genetic abnormalities. Such cases are stratified according to the percentage of blasts:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         AML, not otherwise specified – ≥20 percent blasts
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myelodysplastic syndromes/neoplasms/AML, not otherwise specified – 10 to 19 percent blasts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         AML in patients with a history of prior cytotoxic therapy, antecedent myeloid neoplasms (ie, myelodysplastic syndromes/neoplasms [MDS] or MDS/myeloproliferative neoplasms [MPN]), or an underlying predisposing germline genetic disorder is identified with diagnostic qualifiers, rather than as specific disease categories. As a result, therapy-related myeloid neoplasms and AML with myelodysplasia-related changes were eliminated as designated subtypes. Such cases are described below. (See
         <a class="local">
          'Therapy-related AML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         AML with mutated
         <em>
          TP53
         </em>
         is a separate entity within the group of myeloid neoplasms with mutated
         <em>
          TP53
         </em>
         , which also includes MDS and MDS/AML with mutated
         <em>
          TP53
         </em>
         . (See
         <a class="local">
          'Mutated TP53'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloid Sarcoma
         </strong>
         – An extramedullary mass of myeloid blasts that effaces the normal tissue architecture, as described below. (See
         <a class="local">
          'Myeloid sarcoma'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Down syndrome-related myeloid neoplasms
         </strong>
         – Myeloid proliferations related to Down syndrome, including AML, constitute a distinct category in ICC. (See
         <a class="local">
          'Myeloid proliferations related to Down syndrome'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Blastic plasmacytoid dendritic cell neoplasm
         </strong>
         – Blastic plasmacytoid dendritic cell neoplasm (BPDCN) can present with circulating malignant cells but is distinct from AML, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16911.html" rel="external">
          "Blastic plasmacytoid dendritic cell neoplasm"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3696941674">
         <span class="h2">
          Other AML subtypes in World Health Organization 5th edition
         </span>
         <span class="headingEndMark">
          —
         </span>
         In WHO5, cases that do not have a defining genetic abnormality are categorized according to the level of differentiation of the leukemic cells. The 20 percent threshold to distinguish MDS from AML remains for cases that do not have defining genetic abnormalities; this contrasts with ICC, in which cases with 10 to 20 percent blasts are labeled MDS/AML. (See
         <a class="local">
          'Other AML subtypes in International Consensus Classification'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H671155658">
         <span class="h3">
          AML with minimal differentiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         This category corresponds to 6 percent of cases of what was previously labeled AML, NOS [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         The leukemic blasts are minimally differentiated, with no cytoplasmic granules or Auer rods, and they cannot be distinguished microscopically from lymphoblasts  (
         <a class="graphic graphic_picture graphicRef80658" href="/z/d/graphic/80658.html" rel="external">
          picture 4
         </a>
         ) [
         <a href="#rid55">
          55-57
         </a>
         ].
        </p>
        <p>
         Diagnostic criteria include [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blasts are negative (&lt;3 percent) for myeloperoxidase (MPO) by cytochemistry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expression of ≥2 myeloid-associated antigens, such as CD13, CD33, and CD117
        </p>
        <p>
        </p>
        <p>
         Blasts generally express antigens of early hematopoiesis (eg, CD34, CD117, and CD33) but lack antigens of more mature myeloid cells (eg, CD14, CD15, CD11b, CD64). Expression of terminal deoxynucleotidyl transferase (TdT) and the T cell antigen CD7 may be present.
        </p>
        <p class="headingAnchor" id="H1166587675">
         <span class="h3">
          AML without maturation
         </span>
         <span class="headingEndMark">
          —
         </span>
         This category corresponds to 25 percent of what was previously labeled AML, NOS and 5 to 10 percent of cases of AML [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Blasts account for &gt;90 percent of total cells. The blasts are large with grayish-blue cytoplasm and large nuclei with prominent nucleoli  (
         <a class="graphic graphic_picture graphicRef59646" href="/z/d/graphic/59646.html" rel="external">
          picture 5
         </a>
         ). Some cases contain azurophilic granules and/or Auer rods.
        </p>
        <p>
         Diagnostic criteria for AML without maturation are [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥3 percent blasts positive for MPO (by immunophenotyping or cytochemistry) and negative for nonspecific esterase (NSE) by cytochemistry
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maturing cells of the granulocytic lineage constitute &lt;10 percent of nucleated bone marrow cells
        </p>
        <p>
        </p>
        <p>
         Many cases express antigens of early hematopoiesis (eg, CD34, CD38, human leukocyte antigen [HLA]-DR) and one or more myeloid-associated antigens (eg, CD13, CD33, CD117), but markers of granulocytic maturation (eg, CD15, CD65) are not expressed in most cases.
        </p>
        <p class="headingAnchor" id="H130522866">
         <span class="h3">
          AML with maturation
         </span>
         <span class="headingEndMark">
          —
         </span>
         This category accounts for 10 percent of cases of AML.
        </p>
        <p>
         Blasts account for &lt;90 percent of the marrow cellularity, and maturation is defined by presence of ≥10 percent of bone marrow cells that exhibit differentiation to promyelocytes, myelocytes, and/or mature neutrophils. Blasts may or may not have azurophilic granules and/or Auer rods  (
         <a class="graphic graphic_picture graphicRef68390" href="/z/d/graphic/68390.html" rel="external">
          picture 6
         </a>
         ) [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Diagnostic criteria for AML with maturation are [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥3 percent blasts positive for MPO (by immunophenotyping or cytochemistry) or SBB by cytochemistry.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maturing cells of the granulocytic lineage constitute ≥10 percent of nucleated bone marrow cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cells of monocyte lineage constitute &lt;20 percent of bone marrow cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Expression of ≥2 myeloid-associated antigens, such as MPO, CD13, CD33, and CD117.
        </p>
        <p>
        </p>
        <p>
         Blasts may also express antigens of early hematopoiesis (eg, CD34, CD38, HLA-DR) and those associated with granulocytic maturation (CD65, CD11b, and CD15), but monocytic markers (eg, CD14, CD64) are usually negative.
        </p>
        <p class="headingAnchor" id="H3458659890">
         <span class="h3">
          Acute basophilic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         This is a very rare category of AML in which differentiation is primarily toward basophils. Circulating blasts contain moderately basophilic cytoplasm with variable numbers of coarse basophilic granules that are positive for metachromatic staining with toluidine blue [
         <a href="#rid6">
          6
         </a>
         ]. Clinically, there may be cutaneous involvement, organomegaly, lytic bone lesions, and/or symptoms related to hyperhistaminemia.
        </p>
        <p>
         Diagnostic criteria for acute basophilic leukemia are [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blasts and immature/mature basophils exhibit metachromasia with toluidine blue staining.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blasts are negative for cytochemical MPO and NSE.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No expression of strong CD117 equivalent (to exclude mast cell leukemia).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1320774593">
         <span class="h3">
          Acute myelomonocytic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         This category accounts for 21 percent of AML, NOS [
         <a href="#rid54">
          54
         </a>
         ] and 5 to 10 percent of all AML.
        </p>
        <p>
         The monocytes can be recognized morphologically  (
         <a class="graphic graphic_picture graphicRef58646" href="/z/d/graphic/58646.html" rel="external">
          picture 7
         </a>
         ) by staining with NSE or by immunophenotype (eg, expression of CD14, CD11c, CD64, and lysozyme).
        </p>
        <p>
         Diagnostic criteria for acute myelomonocytic leukemia are [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥20 percent monocytes and their precursors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥20 percent maturing granulocytic cells
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥3 percent of blasts positive for MPO (by immunophenotyping or cytochemistry)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1599981779">
         <span class="h3">
          Acute monocytic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         This category accounts for 15 percent of AML, NOS [
         <a href="#rid54">
          54
         </a>
         ] and 5 to 10 percent of total AML.
        </p>
        <p>
         Monoblasts are large with abundant, moderately to intensely basophilic cytoplasm and may demonstrate pseudopod formation, scattered fine azurophilic granules, and vacuoles. Nuclei are round with delicate lacy chromatin and one or more large prominent nucleoli  (
         <a class="graphic graphic_picture graphicRef51084" href="/z/d/graphic/51084.html" rel="external">
          picture 8
         </a>
         ). Promonocytes are large with less basophilic cytoplasm with occasional large azurophilic granules and vacuoles. The nucleus is irregular with a delicately convoluted configuration  (
         <a class="graphic graphic_picture graphicRef63816" href="/z/d/graphic/63816.html" rel="external">
          picture 9
         </a>
         and
         <a class="graphic graphic_picture graphicRef76635" href="/z/d/graphic/76635.html" rel="external">
          picture 10
         </a>
         ) [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Diagnostic criteria for acute monocytic leukemia are [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥80 percent monocytes and/or their precursors (monoblasts and/or promonocytes)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≤20 percent maturing granulocytic cells
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blasts and promonocytes expressing ≥2 monocytic markers, including CD11c, CD14, CD36 and CD64, or NSE positivity on cytochemistry
        </p>
        <p>
        </p>
        <p>
         Almost all cases express HLA-DR, and myeloid antigens are variably expressed, but at least two markers of monocytic differentiation are expressed.
        </p>
        <p class="headingAnchor" id="H3462283720">
         <span class="h3">
          Acute erythroid leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute erythroid leukemia (AEL; previously called pure erythroid leukemia, erythroleukemia, or Di Guglielmo's disease) accounts for &lt;1 percent of AML, NOS  (
         <a class="graphic graphic_picture graphicRef52638" href="/z/d/graphic/52638.html" rel="external">
          picture 11
         </a>
         ).
        </p>
        <p>
         AEL is a distinct subtype characterized by neoplastic proliferation of erythroid cells with features of maturation arrest and high prevalence of biallelic
         <em>
          TP53
         </em>
         alterations. AEL is characterized by erythroid predominance, which usually constitutes ≥80 percent of bone marrow elements (of which ≥30 percent are proerythroblasts or pronormoblasts). Myeloblasts are &lt;20 percent of all nucleated cells. The erythroblasts react with antibodies to hemoglobin A and glycophorin, and may express CD117, but do not express myeloid markers and do not stain with MPO. In some cases, nucleated erythroid cells constitute &lt;80 percent of bone marrow cellularity; such cases share the same clinicopathologic features of other AEL [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
         Diagnostic criteria for AEL are [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ≥30 percent immature erythroid cells (proerythroblasts)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bone marrow with erythroid predominance, usually ≥80 percent of cellularity
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1715163292">
         <span class="h3">
          Acute megakaryoblastic leukemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute megakaryoblastic leukemia (AMKL), which exhibits maturation in the megakaryocytic lineage, accounts for &lt;1 percent of cases of newly diagnosed AML [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Morphologically, megakaryoblasts are medium to large and have irregular or indented nuclei and basophilic cytoplasm with blebs or pseudopod formation. Small and large megakaryocytes may be admixed with blasts. Adults with AMKL have a high incidence of an antecedent hematologic disorder, MDS, and/or prior chemotherapy [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Diagnosis requires that blasts express at least one of the following platelet glycoproteins: CD41 (glycoprotein llb), CD61 (glycoprotein llla), or CD42b (glycoprotein lb) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Certain categories of leukemia that resemble AMKL are now considered distinct entities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myeloid leukemia in children with Down syndrome or trisomy 21 is a distinct entity, called myeloid leukemia associated with Down syndrome. (See
         <a class="medical medical_review" href="/z/d/html/139448.html" rel="external">
          "Myeloid leukemia associated with Down syndrome (ML-DS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AMKL in children and infants without Down syndrome or trisomy 21 may be associated with cryptic inversion of chromosome 16 and the
         <em>
          CBFA2T3::GLIS2
         </em>
         fusion [
         <a href="#rid63">
          63
         </a>
         ], t(1;22) with
         <em>
          RBM15::MRTFA
         </em>
         [
         <a href="#rid64">
          64
         </a>
         ], or t(5;11) with
         <em>
          NUP98::KDM5A
         </em>
         [
         <a href="#rid65">
          65
         </a>
         ]. These are included in the category AML with other defined genetic alterations. (See
         <a class="local">
          'Other genetic abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2945798854">
         <span class="h1">
          SPECIAL CATEGORIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classification of special categories of AML and related disorders differ between the International Consensus Classification (ICC) and World Health Organization 5th edition (WHO5).
        </p>
        <p class="headingAnchor" id="H813376731">
         <span class="h2">
          Therapy-related AML
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapy-related AML is diagnosed when AML arises in a patient with prior exposure to cytotoxic agents, ionizing radiation, or immune interventions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – "Therapy-related" is added as a qualifier following a diagnosis of AML, myelodysplastic syndromes/neoplasms (MDS), or MDS/AML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Myeloid neoplasms that arise secondary to exposure to cytotoxic therapy are included in the category of secondary myeloid neoplasms (which also includes AML in association with a germline predisposition).
        </p>
        <p>
        </p>
        <p>
         Details of the diagnosis and treatment of therapy-related myeloid malignancies are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">
          "Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4032976264">
         <span class="h2">
          Predisposing genetic conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         AML and related myeloid disorders can be associated with germline or inherited gene variants (mutations) mostly in children, but they can also arise in adults.
        </p>
        <p>
         Myeloid malignancies in the setting of a germline condition may be in association with platelet disorders and chronic thrombocytopenia, constitutional disorders that affect multiple organ systems, or without associated conditions. Many of the affected genes predispose not only to myeloid malignancies but also to lymphoid malignancies. (See
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes"
         </a>
         .)
        </p>
        <p>
         A careful family history is important at the time of diagnosis to identify patients with AML who have a germline predisposition. Recognizing this association enables proper diagnosis and management of AML, screening of related donors for allogeneic hematopoietic cell transplantation (HCT), selection of an appropriate transplant conditioning regimen, and genetic counseling for affected family members. A high index of suspicion of germline mutation is important, especially for younger patients with AML and for those who will be transplanted using related donors.
        </p>
        <p>
         An underlying germline variant gene or syndrome should be specified as a qualifier after the diagnosis of AML or another hematologic malignancy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus classification
         </strong>
         – Myeloid malignancies in association with a germline predisposition constitute a separate category and are included in one of the following groups [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematologic neoplasms with germline predisposition without a constitutional disorder affecting multiple organ systems
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematologic neoplasms with germline predisposition associated with a constitutional platelet disorder
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Hematologic neoplasms with germline predisposition associated with a constitutional disorder affecting multiple organ systems
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Myeloid malignancies in association with a germline predisposition are included in the category secondary myeloid neoplasms (which also includes therapy-related AML) in one of the following groups [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Myeloid neoplasms with germline predisposition without a pre-existing platelet disorder or organ dysfunction
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Myeloid neoplasms with germline predisposition and pre-existing platelet disorder
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Myeloid neoplasms with germline predisposition and potential organ dysfunction
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1476337256">
         <span class="h2">
          Myeloid sarcoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myeloid sarcoma refers to an extramedullary mass of myeloid blasts that effaces the normal tissue architecture. It may precede, present simultaneously with, or follow a diagnosis of AML in bone marrow/blood, or it can occur in relapse or progression of prior MDS or myeloproliferative neoplasms (MPN). Myeloid sarcoma is sometimes the first site of relapse after allogeneic HCT for a myeloid neoplasm.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification
         </strong>
         – Myeloid sarcoma constitutes a subtype of AML in the ICC classification [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition
         </strong>
         – Myeloid sarcoma is considered a tissue-based manifestation of AML [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Treatment of patients with myeloid sarcoma without evidence of AML on bone marrow or blood is like that for patients with overt AML. (See
         <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Myeloid sarcoma'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2998367550">
         <span class="h2">
          Myeloid proliferations related to Down syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myeloid proliferations related to Down syndrome include two entities that develop in the setting of trisomy 21 [
         <a href="#rid66">
          66
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transient abnormal myelopoiesis
         </strong>
         –
         <strong>
         </strong>
         Transient abnormal myelopoiesis (TAM) refers to myeloid proliferation that occurs in 10 to 30 percent of newborns with Down syndrome. The disorder is usually characterized by blasts that arise during fetal development in an individual with trisomy 21 plus acquisition of a somatic mutation of
         <em>
          GATA1
         </em>
         . TAM is usually diagnosed at or around birth, and most cases resolve within one to two months, although there is a risk of early mortality and subsequent AML, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/16914.html" rel="external">
          "Transient abnormal myelopoiesis (TAM) of Down syndrome (DS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloid leukemia associated with Down syndrome
         </strong>
         – Approximately 20 percent of children with TAM develop myeloid leukemia associated with Down syndrome within the first four years of life. In one-third of cases, myeloid leukemia associated with Down syndrome follows a prodrome of an MDS-like period of chronic cytopenias [
         <a href="#rid67">
          67
         </a>
         ]. Most cases are classified as acute megakaryoblastic leukemia. This is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13935.html" rel="external">
          "Acute myeloid leukemia in children and adolescents", section on 'Down syndrome and AML'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26564681">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Acute myeloid leukemia (AML) is a heterogeneous category of aggressive myeloid malignancies characterized by an accumulation of myeloid blasts in bone marrow, blood, or other tissues and distinguished by arrested myeloid maturation. Classification of AML has evolved with a greater understanding of causes, cytogenetic and molecular features, prognosis, and management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Classification systems
         </strong>
         – Two classification systems for hematologic malignancies that rely heavily on cytogenetic and molecular features of leukemic blasts were published in 2022. (See
         <a class="local">
          'Classification systems'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of either model is acceptable, and they supersede previous classification systems:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          International Consensus Classification of Myeloid Neoplasms and Acute Leukemia
         </strong>
         (see
         <a class="local">
          'International Consensus Classification'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          World Health Organization 5th edition (WHO5) myeloid and histiocytic/dendritic neoplasms
         </strong>
         (see
         <a class="local">
          'World Health Organization 5th edition'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         These models have many similarities, but they use different systems for classification of AML, and they differ regarding certain diagnostic criteria and labels for AML subtypes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparison of classification systems
         </strong>
         – Both International Consensus Classification (ICC) and World Health Organization 5th edition (WHO5) rely heavily on genetic features of AML, and they share many aspects of organization for cases with defining genetic abnormalities. They differ substantially in how they define, categorize, and label cases of AML that lack such defining genetic features and in cases that arise after prior cytotoxic therapy or in association with predisposing germline (inherited) gene variants. (See
         <a class="local">
          'Comparison of International Consensus Classification and World Health Organization 5th edition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AML with defining genetic abnormalities
         </strong>
         – Most cases of AML have a defining genetic abnormality. Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Acute promyelocytic leukemia with t(15;17)/
         </strong>
         <strong>
          <em>
           PML::RARA
          </em>
         </strong>
         (see
         <a class="local">
          'Acute promyelocytic leukemia with PML::RARA'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          t(8;21)/
         </strong>
         <strong>
          <em>
           RUNX1::RUNX1T1
          </em>
         </strong>
         (see
         <a class="local">
          't(8;21)/RUNX1::RUNX1T1'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          inv(16)(p13.1q22) or t(16;16)(p13.1;q22);
         </strong>
         <strong>
          <em>
           CBFB-MYH11
          </em>
         </strong>
         (see
         <a class="local">
          'inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB::B-MYH11'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          t(9;11)(p21.3;q23.3);
         </strong>
         <strong>
          <em>
           MLLT3-KMT2A
          </em>
         </strong>
         (see
         <a class="local">
          't(9;11)(p21.3;q23.3); MLLT3::KMT2A'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2);
         </strong>
         <strong>
          <em>
           GATA2
          </em>
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          <em>
           MECOM
          </em>
         </strong>
         <em>
         </em>
         (see
         <a class="local">
          'inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          <em>
           BCR::ABL1
          </em>
         </strong>
         <em>
         </em>
         (see
         <a class="local">
          'BCR::ABL1'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mutated
         </strong>
         <strong>
          <em>
           NPM1
          </em>
         </strong>
         (see
         <a class="local">
          'Mutated NPM1'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mutated
         </strong>
         <strong>
          <em>
           CEBPA
          </em>
         </strong>
         (see
         <a class="local">
          'Mutated CEBPA'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mutated
         </strong>
         <strong>
          <em>
           TP53
          </em>
         </strong>
         (see
         <a class="local">
          'Mutated TP53'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myelodysplasia-related gene mutations
         </strong>
         (see
         <a class="local">
          'Myelodysplasia-related gene mutations'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myelodysplasia-related cytogenetic abnormalities
         </strong>
         (see
         <a class="local">
          'Myelodysplasia-related cytogenetic abnormalities'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other AML subtypes
         </strong>
         – ICC and WHO5 differ in how they classify AML without a defining genetic abnormality.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other International Consensus Classification subtypes
         </strong>
         – Most such cases are AML, not otherwise specified.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other World Health Organization 5th edition subtypes
         </strong>
         – Cases without a defining genetic feature are classified according to differentiation of blasts.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special categories
         </strong>
         – ICC and WHO5 differ in how they categorize and label the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Therapy related
         </strong>
         (see
         <a class="local">
          'Therapy-related AML'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Predisposing genetic conditions
         </strong>
         (see
         <a class="local">
          'Predisposing genetic conditions'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myeloid sarcoma
         </strong>
         (see
         <a class="local">
          'Myeloid sarcoma'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Myeloid proliferations related to Down syndrome
         </strong>
         (see
         <a class="local">
          'Myeloid proliferations related to Down syndrome'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H980818387">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate acknowledges John Anastasi, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med 2016; 374:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cancer Genome Atlas Research Network, Ley TJ, Miller C, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368:2059.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science 2019; 366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140:1200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36:1703.
          </a>
         </li>
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen L, Xu Y, Yao L, et al. Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions. Haematologica 2019; 104:e195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quessada J, Cuccuini W, Saultier P, et al. Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge. Genes (Basel) 2021; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang JL, Hou HA, Chen CY, et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009; 114:5352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendler JH, Maharry K, Radmacher MD, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 2012; 30:3109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khoury H, Dalal BI, Nevill TJ, et al. Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotype. Leuk Lymphoma 2003; 44:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992; 80:3182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992; 80:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiacci E, Pileri S, Orleth A, et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia. Cancer Res 2004; 64:7399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peniket A, Wainscoat J, Side L, et al. Del (9q) AML: clinical and cytological characteristics and prognostic implications. Br J Haematol 2005; 129:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92:2322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willekens C, Blanchet O, Renneville A, et al. Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial. Haematologica 2016; 101:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes R, Keating MJ, Cork A, et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985; 65:1071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohyashiki K, Ohyashiki JH, Iwabuchi A, et al. Central nervous system involvement in acute nonlymphocytic leukemia with inv(16)(p13q22). Leukemia 1988; 2:398.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwind S, Edwards CG, Nicolet D, et al. inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. Blood 2013; 121:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Creutzig U, Harbott J, Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood 1995; 86:3097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz L, Nomdedéu JF, Villamor N, et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100:4325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mrózek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 1997; 90:4532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winters AC, Bernt KM. MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches. Front Pediatr 2017; 5:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forestier E, Heim S, Blennow E, et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Br J Haematol 2003; 121:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006; 20:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oyarzo MP, Lin P, Glassman A, et al. Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations. Am J Clin Pathol 2004; 122:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chi Y, Lindgren V, Quigley S, Gaitonde S. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med 2008; 132:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96:4075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pintado T, Ferro MT, San Román C, et al. Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy. Cancer 1985; 55:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bitter MA, Neilly ME, Le Beau MM, et al. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985; 66:1362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang VT, Aviv H, Howard LM, Padberg F. Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature. Am J Hematol 2003; 72:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gröschel S, Sanders MA, Hoogenboezem R, et al. A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia. Cell 2014; 157:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamazaki H, Suzuki M, Otsuki A, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 2014; 25:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lugthart S, Gröschel S, Beverloo HB, et al. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol 2010; 28:3890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reiter E, Greinix H, Rabitsch W, et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26). Ann Hematol 2000; 79:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers HJ, Vardiman JW, Anastasi J, et al. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica 2014; 99:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Secker-Walker LM, Mehta A, Bain B. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. Br J Haematol 1995; 91:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atfy M, Al Azizi NM, Elnaggar AM. Incidence of Philadelphia-chromosome in acute myelogenous leukemia and biphenotypic acute leukemia patients: And its role in their outcome. Leuk Res 2011; 35:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neuendorff NR, Burmeister T, Dörken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol 2016; 95:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nacheva EP, Grace CD, Brazma D, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 2013; 161:541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1-mutated acute myeloid leukemia: from bench to bedside. Blood 2020; 136:1707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Döhner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106:3740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasqualucci L, Liso A, Martelli MP, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification. Blood 2006; 108:4146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nomdedéu J, Hoyos M, Carricondo M, et al. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. Leuk Res 2012; 36:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taube F, Georgi JA, Kramer M, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood 2022; 139:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakita S, Sakaguchi M, Oh I, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv 2022; 6:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter RB, Othus M, Burnett AK, et al. Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 2013; 121:2424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee EJ, Pollak A, Leavitt RD, et al. Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood 1987; 70:1400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Béné MC, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol 2001; 113:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roumier C, Eclache V, Imbert M, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH). Blood 2003; 101:1277.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haferlach T, Schoch C, Schnittger S, et al. Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients. Br J Haematol 2002; 118:426.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu W, Hasserjian RP, Hu Y, et al. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol 2011; 24:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SA, Hasserjian RP. Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities. Am J Clin Pathol 2015; 144:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oki Y, Kantarjian HM, Zhou X, et al. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 2006; 107:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masetti R, Bertuccio SN, Pession A, Locatelli F. CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity. Br J Haematol 2019; 184:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 2001; 28:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Rooij JD, Branstetter C, Ma J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes. Nat Genet 2017; 49:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boucher AC, Caldwell KJ, Crispino JD, Flerlage JE. Clinical and biological aspects of myeloid leukemia in Down syndrome. Leukemia 2021; 35:3352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorrell AD, Alonzo TA, Hilden JM, et al. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group. Cancer 2012; 118:4806.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 86098 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27276561" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Genomic Classification and Prognosis in Acute Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23634996" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31672865" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clonal hematopoiesis in human aging and disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35767897" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35732831" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3862359" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385793" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30237272" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical and molecular features of acute promyelocytic leukemia with variant retinoid acid receptor fusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27069254" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7795214" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34204358" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19808697" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753902" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14692523" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Acute myelogenous leukemia with t(8;21)--identification of a specific immunophenotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1467524" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1378322" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15492262" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15813849" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Del (9q) AML: clinical and cytological characteristics and prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9746770" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26635039" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3857943" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3163744" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Central nervous system involvement in acute nonlymphocytic leukemia with inv(16)(p13q22).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3163744" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Central nervous system involvement in acute nonlymphocytic leukemia with inv(16)(p13q22).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23160462" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7579404" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12529663" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393746" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9373264" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28232907" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12752097" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16628187" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15362364" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Acute myeloid leukemia with t(6;9)(p23;q34) is associated with dysplasia and a high frequency of flt3 gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976025" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11110676" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3965107" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4063525" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12508263" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Acute myelogenous leukemia associated with extreme symptomatic thrombocytosis and chromosome 3q translocation: case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24703711" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24703906" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20660833" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10965785" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inversioin inv (3)(q21q26) or homologous translocation t(3;3) (q21;q26).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24463215" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8547101" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21612824" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Incidence of Philadelphia-chromosome in acute myelogenous leukemia and biphenotypic acute leukemia patients: And its role in their outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27297971" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23521501" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Does BCR/ABL1 positive acute myeloid leukaemia exist?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32609823" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : NPM1-mutated acute myeloid leukemia: from bench to bedside.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16051734" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16926285" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22520341" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34320176" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34448807" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23325837" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3663939" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Minimally differentiated acute nonlymphocytic leukemia: a distinct entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380465" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acute myeloid leukaemia M0: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393381" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393381" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Français d'Hématologie Cellulaire (GFHC) and the Groupe Français de Cytogénétique Hématologique (GFCH).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12139726" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21102413" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26071461" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics: A Guide to a Number of Perplexing Entities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16123215" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30592296" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11431691" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28112737" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34518645" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clinical and biological aspects of myeloid leukemia in Down syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22392565" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
